Medtronic PLC (NYSE:MDT) Receives Average Rating of “Moderate Buy” from Brokerages

Medtronic PLC (NYSE:MDT) has been assigned an average recommendation of “Moderate Buy” from the twenty-six ratings firms that are currently covering the firm, Marketbeat.com reports. Twelve equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $109.9444.

A number of equities analysts recently issued reports on MDT shares. Morgan Stanley increased their target price on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Robert W. Baird set a $103.00 price target on shares of Medtronic in a research note on Tuesday. Royal Bank Of Canada increased their price objective on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Finally, Truist Financial cut their target price on Medtronic from $110.00 to $107.00 and set a “hold” rating for the company in a research report on Thursday.

Medtronic Stock Up 0.2%

Shares of Medtronic stock opened at $98.54 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. Medtronic has a 1-year low of $79.29 and a 1-year high of $106.33. The business’s fifty day moving average price is $97.32 and its two-hundred day moving average price is $93.25. The company has a market capitalization of $126.33 billion, a P/E ratio of 26.56, a PEG ratio of 2.59 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The company had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same period last year, the company earned $1.26 earnings per share. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be issued a $0.71 dividend. The ex-dividend date is Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. Medtronic’s dividend payout ratio is 76.55%.

Institutional Investors Weigh In On Medtronic

Several hedge funds and other institutional investors have recently bought and sold shares of MDT. 1248 Management LLC acquired a new position in shares of Medtronic in the 1st quarter worth approximately $26,000. Delos Wealth Advisors LLC acquired a new stake in Medtronic during the second quarter valued at approximately $27,000. Corundum Trust Company INC bought a new stake in Medtronic during the third quarter worth approximately $27,000. Twin Tree Management LP bought a new stake in Medtronic during the first quarter worth approximately $29,000. Finally, Valley Wealth Managers Inc. acquired a new position in Medtronic in the third quarter worth approximately $29,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.